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license (http://creativehas yet explored relationships between deficits in cerebrovascular function, cognitive performance,
and mood in postmenopausal women.
Method: Cerebrovascular function was assessed in 80 healthy postmenopausal women by moni-
toring blood flow velocity (BFV) in the middle and posterior cerebral arteries using transcranial
Doppler ultrasound at rest, following a hypercapnic challenge, and during performance of a cognitive
test battery; the latter assessed domains of memory and executive functions. Various measures of
mood (i.e., Profile of Mood States and Center for Epidemiological Studies Depression Scale) were
also assessed.
Results: Cerebral artery elasticity and BFV responsiveness to cognitive tests (neurovascular
coupling) correlated with cognitive performance but not with depressive symptoms or mood states.
Mood deficits were related to poor cognitive performance.
Conclusion: These results highlight the importance of adequate cerebral perfusion for optimized
cognitive function in healthy postmenopausal women. Preventative strategies to attenuate accelerated
cognitive decline should also consider restoring cerebrovascular function.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Menopause; Cerebrovascular function; Pulsatility index; Depression; Mood; Cognition1. Introduction
Complaints of decreased mental clarity and mood swings
are common during the menopausal transition [1]. Although
these symptoms may be situational at this time of life, for
example, health issues, stress of caring for aging parents, or
“empty nest syndrome”, we cannot ignore that the prevalence
of Alzheimer’s disease, most common form of dementia, is
higher in elderly women than men [2]. Although the biolog-
ical basis for this heightened risk in women remains to be es-
tablished, basic and clinical evidence indicate that the rapid
decline in estrogen at onset of menopause has adverse conse-
quences, particularly for the brain [3,4]. Higher endogenousthor. Tel.: 161-02-4921-4608.
achel.wong@newcastle.edu.au
16/j.trci.2016.07.003
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).estrogen has been shown to be associated with better
cognitive function in postmenopausal midlife women
(w60 years old), particularly for semantic and verbal
memory [5].
From a vascular perspective, estrogen can also bind to es-
trogen receptors on the endothelium of cerebral arteries,
causing vasodilatation and thereby increasing perfusion of
brain regions in response to need [6]. Hence, estrogen defi-
ciency after menopause rather than aging per se is thought
to contribute to the large reduction in cerebral vasodilator
responsiveness (CVR) in postmenopausal women compared
with premenopausal women and elderly men [7]. Evidence
of associations between impaired CVR and cerebral arterial
stiffness and severity of dementia is well established [8,9].
Impaired CVR is evident in those with major depression,
suggesting that optimal cerebrovascular function may be
critical for optimal brain function independent of seximer’s Association. This is an open access article under the CC BY-NC-ND
R.H.X. Wong et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 162-168 163hormones [10]. With the increased life expectancy in the
aging population, extension of the postmenopausal period
may result in reduced quality of life in latter years, due to
prolonged cerebral hypoperfusion, thereby adversely
affecting cognitive abilities and mood [11].
Recovery from depression is possible by improving cere-
bral perfusion [12]. However, no studies have yet explored
relationships between CVR to physiological or cognitive de-
mands and either mood states or cognitive performance in
postmenopausal women. Understanding if such relation-
ships exist can help tailor early interventions to attenuate
these deficiencies so as to assist older women achieve quality
of life.
We are currently investigating whether a 14-week dietary
supplementation with a phytoestrogen, viz., resveratrol, can
improve cerebral perfusion and thereby enhance cognitive
performance and mood in postmenopausal women who are
not taking HRT (Clinical Trial Registration no:
ANZCTR12615000291583). Assessments of cerebrovascu-
lar function, cognitive performance in specific cognitive do-
mains implicated in mood states, and depressive symptoms
in postmenopausal women were obtained at baseline to
examine the relationships between cerebrovascular function,
cognitive function, and mood in this cohort.2. Method
All potential volunteers gave written informed consent
before attending the Clinical Nutrition Research Centre,
University of Newcastle, for the assessments of outcomes
at baseline (see [13] for details of study protocol and descrip-
tion of the assessments). Arriving at the center after a 1-hour
fast, they undertook the Australian version of the modified
Mini-Mental State Examination (3MS) to exclude those
with suspected dementia (score of ,78/100). Their 3MS
scores were also used as a measure of global cognition as
administration of this assessment does not require high level
of training and frequently used in clinical settings [14].
Menopausal symptoms were quantified using the Meno-
pausal Rating Scale [15] and used as a covariate in this
exploratory analysis as they have been shown to affect
mood and cognitive function [16]. The order of assessments
was conducted as follows with at least a 2-minute interval
between each test.2.1. Basal cerebral hemodynamics
Transcranial Doppler ultrasound (Doppler-Box X, Sin-
gen, Germany) is a noninvasive technique to assess blood
flow velocity (BFV) in the brain. Using an adjustable head-
piece, the middle and posterior cerebral arteries (MCA and
PCA, respectively) on both the left and right sides were iso-
lated using the transtemporal window as this provides the
least interference during insonation [17]. A 30-s continuous
recording of basal BFV (maximum, mean, minimum) in the
MCA and the PCAwas obtained before hypercapnic provo-cation and before the start of each cognitive test. The
Gosling pulsatility index (PI) and Pourcelot resistive index
(RI) reflecting intracranial vessel stiffness and the basal
mean BFV were determined by averaging the last 10 s of
the 30-s basal recording. PI and RI are calculated as follows:
PI 5 (maximum BFV 2 minimum BFV)/mean BFV; RI 5
(maximum BFV 2 minimum BFV)/maximum BFV.
Although PI and RI are linearly correlated and reflect intra-
cranial vascular resistance [18], RI is arguably a better
reflection of resistance as it combines vascular compliance
in the arterial waveform, which is modifiable by blood pres-
sure (BP), age, and medication use [19]. The PI/mean BFV
ratio (multiplied by 100 for ease of reporting) was also deter-
mined; it is a recognized index of intracranial vascular
disease [20].
2.2. Cerebrovascular responsiveness
Increases in BFV in the cerebral vessels in response to
physiological (i.e., hypercapnia) or cognitive stimuli are in-
direct measures of cerebrovascular responsiveness (CVR);
they reflect the extent of vasodilator capacity in downstream
vascular beds [21]. To assess CVR to hypercapnia, volun-
teers inhaled a carbogen gas mixture (5% CO2, 95% O2)
through a two-way nonrebreathing mouthpiece for 180 sec-
onds, which elicited an acute increase in BFV. The ultra-
sound probes were kept in position throughout the
cognitive assessments to determine CVR to cognitive stimuli
in the MCA during each cognitive task. CVR to hypercapnia
or cognitive stimuli is calculated as the peak increase in
mean BFV, expressed as a percentage of the mean BFV re-
corded under basal conditions.
2.3. Cognitive performance
In addition to the 3MS, we also used a neuropsychologi-
cal test battery that is more sensitive to capture deficits in
cognitive domains known to be negatively affected in post-
menopausal women, namely semantic [22], verbal [1], and
visual spatial working memory [23], as well as executive
function, shown to decline with age irrespective of gender
[24]. The battery consisted of the Rey Auditory Verbal
Learning Test [25], the Cambridge Semantic Memory Bat-
tery [26], the Double Span [27], and the Trail Making
Task [28]. Performances on each test were converted to Z
scores and were summated to determine their overall cogni-
tive performance.
2.4. Assessment of mood
Participants’ mood states were assessed using two
different indices, the Profile of Mood States version 2, and
the Center for Epidemiological Studies Depression Scale.
The Profile of Mood States questionnaire assessed how the
participant was feeling over the last week (including the
day of the visit) through 65 adjectives that the participant
rated on a 5-point Likert scale (1 being “not at all” and 5
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sure of mood states and their fluctuations. A calculated score
denoting “total mood disturbances” was used to determine
overall mood state [29]. The depression scale is a commonly
used tool to characterize depressive symptoms in the general
population [30]; its sensitivity is ideal for detecting depres-
sive symptoms in postmenopausal women [31].2.5. Statistical analysis
Statistical analyses were performed using SPSS, version
21.0 (SPSS by IBM Inc., Chicago, IL). Pearson’s correla-
tions were used to determine the relationships between basal
cerebral hemodynamics, CVR to hypercapnia and cognitive
stimuli, global cognition (3MS), overall cognitive perfor-
mance, depressive symptoms, and total mood disturbances.
Age was entered as a covariate in all the analysis. Meno-
pausal symptoms, years of menopause, and years of formal
education were considered as covariates if they correlated
significantly with the outcome assessments. The level of sig-
nificance was set at P 5 .05, and no adjustments were made
for multiple comparisons in this exploratory analysis.3. Results
3.1. Participant characteristics
Participant characteristics are detailed in Table 1. The 80
postmenopausal women assessed were normotensive but
slightly overweight, and their mean waist circumference of
.80 cm is consistent with postmenopausal fat redistribution.Table 1
Participant characteristics of 80 postmenopausal women obtained at
baseline
Characteristics Mean 6 SEM
Age (y) 61.5 6 0.8
Years since onset of menopause 11.4 6 0.9
Education years 15.5 6 0.5
3MS (% accuracy) 96.1 6 0.4
BMI (kg/m2) 26.71 6 0.57
Waist circumference (cm) 87.0 6 1.4
Systolic BP (mm Hg) 125.3 6 1.5
Diastolic BP (mm Hg) 70.9 6 1.0
MCA
Basal mean BFV (cm/s) 49.36 6 1.39
Pulsatility index (PI) 0.83 6 0.02
Resistive index 0.55 6 0.01
PI/mean BFV 1.76 6 0.08
CVR to hypercapnia (%) 51.33 6 1.60
PCA
Basal mean BFV (cm/s) 41.14 6 1.52
Pulsatility index (PI) 0.93 6 0.02
Resistive index 0.59 6 0.01
PI/mean BFV 2.34 6 0.11
CVR to hypercapnia (%) 56.32 6 2.31
Abbreviations: BP, blood pressure; MCA, middle cerebral arteries; BFV,
blood flow velocity; CVR, cerebral vasodilator responsiveness; PCA, poste-
rior cerebral arteries.Their 3MS scores and years of formal education were indic-
ative of a high level of cognitive functioning. One quarter of
the cohort (n5 20) had previously taken HRT for an average
of 9.8 6 1.2 years. Eight had been hysterectomized due to
prolapse. However, no further data on their surgical history
or whether these women had oophorectormy were collected.
In the MCA, their basal PI was 0.83 6 0.02, which was
lower than values of 0.87–0.97 for 60-to-80-year-old healthy
women reported in the literature [15]. In the PCA, the PI of
0.93 6 0.02 was similar to values previously reported [15].
None of the women were clinically diagnosed or medi-
cated for depression, yet 12 women had a depressive symp-
tom score of 16, suggestive of depression [32].3.2. Relationships between assessments of
cerebrovascular function in anterior and posterior arteries
There were no bilateral differences for basal MBFV, RI,
PI, PI/mean BFV, and CVR to hypercapnia in the MCA
and PCA (data not shown); thus, values were averaged
from left and right arteries to give a combined value
(Table 1).
The vessel stiffness (PI, RI, and PI/mean BFV) and BFV
of the MCA correlated positively with those in the PCA (PI:
r 5 0.574; RI: r 5 0.609; PI/mean BFV: r 5 0.582; Basal
BFV: r 5 0.703, P , .001; n 5 40).
There was a positive correlation between CVR to hyper-
capnia obtained in the MCA and in the PCA (r 5 0.551,
P, .001, n5 41). CVR to cognitive stimuli correlated posi-
tively with CVR to hypercapnia in the PCA (r 5 0.446,
P 5 .003 n 5 41) but not in the MCA (r 5 0.109,
P 5 .401, n 5 62).3.3. Cognition and mood
Years of education did not correlate with 3MS scores
(r 5 0.093, P 5 .414) or overall cognitive performance
(r 5 0.152, P 5 .177) hence was not used as a covariate in
this correlational analysis. Menopausal symptoms have an
influence on mood (depressive symptoms: r 5 0.639,
P , .001; total mood disturbances: r 5 0.618, P , .001)
but not on 3MS (r520.203, P5 .072) or overall cognitive
performance (r 5 20.067, P 5 .556). Years since meno-
pause did not correlate with 3MS (r 5 0.034, P 5 .766) or
overall cognitive performance (r 5 20.056, P 5 .621) or
with depression scores (r 5 20.120, P 5 .294) or total
mood disturbances (r 5 0.00, P 5 .999). Thus, only meno-
pausal symptoms were controlled for in the correlational
analysis relating to mood.
Volunteers’ performance on the 3MS (global cognition)
correlated with their overall performance on the cognitive
test battery (r 5 0.589, P , .001). Overall cognitive perfor-
mance but not 3MS scores was related to depression scores
(3MS: r520.206 P5 .076; overall cognitive performance:
r 5 20.275, P 5 .016; n 5 74). Similarly, overall perfor-
mance on the cognitive test battery also correlated with total
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mood disturbances did not correlate with 3MS (global cogni-
tion; r 5 20.106, P 5 .362, n 5 74).
3.4. Cerebrovascular function and cognitive function
Table 2 shows the correlations between cerebrovascular
function in the MCA and PCA and cognitive function before
and after controlling for age and menopausal years. After ad-
justments, PI/mean BFV in both the MCA and the PCA
correlated negatively with 3MS score and overall cognitive
performance on the test battery. High PI and RI in the
MCA and PCA also negatively correlated with global cogni-
tion. Only higher basal mean BFVmeasured in the PCA pre-
dicted better overall performance on the test battery. Overall
cognitive performance on the test battery was dependent on
CVR in the MCA during task activation. In contrast, CVR to
hypercapnia in the MCA correlated negatively with global
cognition.3.5. Cerebrovascular function and mood
Table 3 shows the correlations between cerebrovascular
parameters in the MCA and PCA and mood, with and
without controlling for age, menopausal years, and symp-
toms. High PI and RI in the MCA correlated with depression
score and total mood disturbances but disappeared after con-
trolling for these covariates.
4. Discussion
Our cross-sectional findings provide evidence of a
plausible link between cerebrovascular function and both
mood and cognitive performance in postmenopausalTable 2










Basal mean BFV 0.233 .058 0.291
Pulsatility index (PI) 20.212 .085 20.292
Resistive index 20.175 .156 20.244
PI/mean BFV 20.303 .013* 20.448
CVR to hypercapnia 20.289 .020* 20.162
CVR to cognitive test battery 0.251 .045* 0.301
PCA
Basal mean BFV 0.106 .516 0.218
Pulsatility index (PI) 20.527 ,.001* 20.280
Resistive index 20.498 .001* 20.122
PI/mean BFV 20.336 .034* 20.318
CVR to hypercapnia 20.010 .948 0.079
Abbreviations: BP, blood pressure; MCA, middle cerebral arteries; BFV, blood
rebral arteries.
*P , .05.women. After controlling for age, menopausal years, and
symptoms, it appears that basal cerebral BFV, intracranial
artery elasticity, and CVR to a cognitive test battery are asso-
ciated with cognitive performance but not depressive symp-
toms or mood states. Cognitive performance was affected by
mood deficits.
Performance on the cognitive test battery was dependent
on basal BFV and intracranial artery elasticity, whereby
lower basal BFV and greater stiffness were associated with
poorer cognitive performance. We observed that in both
the MCA and PCA, PI/mean BFV was a better predictor
of performance on the 3MS, a crude measure of global
cognition, and on a comprehensive neuropsychological test
battery than PI or RI alone. The combination of low BFV
and high PI (represented by PI/mean BFV) has been associ-
ated with diffuse stenosis of intracranial arterioles in stroke
patients and can lead to chronic hypoperfusion [33]. Over
time, the ischemic environment may lead to loss of neuronal
function [34], which may explain previous neuroimaging ev-
idence of cerebral hypoperfusion in dementia patients [35].
Our observation that high PI/mean BFV is associated with
poor cognition in healthy postmenopausal women indepen-
dent of age provides evidence linking intracranial vessel
stiffness to cognitive impairment. Emerging evidence also
indicates that postmenopausal women with poor metabolic
profile have significantly lower cognitive function compared
with healthy women [36]. Adults with type 2 diabetes have
lower BFV in theMCA and elevated PI [37] and have greater
risk of accelerated cognitive impairment in later life [38].
CVR to hypercapnia is reflective of the global compensa-
tory dilatory capacity of cerebral vessels to a physiological
stimulus. Impairment of CVR to hypercapnia has been
implicated in the severity of cognitive impairment in patientsCA and cognition before and after controlling for age and menopausal years
ognitive
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.017* 0.137 .310 0.240 .072
.016* 20.319 .019* 20.219 .102
.046* 20.264 .047* 20.142 .291
,.001* 20.273 .040* 20.393 .003*
.194 20.341 .036* 20.163 .224
.016* 0.194 .148 0.316 .017*
.177 0.134 .430 0.379 .021*
.080 20.514 .001* 20.210 .212
.453 20.533 .001* 20.073 .660
.046* 20.327 .048* 20.380 .020*
.622 20.068 .688 0.072 .674
flow velocity; CVR, cerebral vasodilator responsiveness; PCA, posterior ce-
Table 3








r P r P r P r P
MCA
Basal mean BFV 20.131 .294 20.054 .665 0.008 .956 0.037 .791
Basal PI 20.305 .013* 20.182 .144 20.101 .463 20.026 .849
Basal RI 20.306 .012* 20.199 .110 20.098 .479 20.044 .750
PI/mean BFV 20.094 .451 20.047 .706 20.123 .372 20.101 .463
CVR to hypercapnia 20.211 .092 20.229 .066 20.134 .330 20.172 .209
CVR to cognitive stimuli 20.067 .602 20.187 .143 0.078 .573 20.094 .495
PCA
Basal mean BFV 20.094 .564 20.108 .509 0.124 .466 0.034 .841
Basal PI 0.004 .980 0.015 .929 20.049 .773 20.026 .880
Basal RI 20.053 .744 20.081 .619 20.128 .452 20.164 .331
PI/mean BFV 0.084 .608 0.073 .653 20.186 .272 20.141 .406
CVR to hypercapnia 20.146 .361 20.117 .467 20.115 .498 20.058 .735
Abbreviations: MCA, middle cerebral arteries; BFV, blood flow velocity; CVR, cerebral vasodilator responsiveness; PCA, posterior cerebral arteries; RI,
resistive index.
*P , .05.
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mentia [8]. It was surprising to observe that enhanced
CVR to hypercapnia in the MCA correlated with poorer
3MS scores in our analysis. However, this correlation did
not exist with the CVR to hypercapnia in the PCA or with
overall cognitive performance on the test battery. Although
the 3MS is used routinely in clinics to screen for suspected
dementia in those with subjective cognitive complaints, it
is relatively insensitive for detecting subtle cognitive
changes in normal functioning adults [39]. Considering
that the 3MS was administered as part of our study inclusion
screening protocol before the cognitive test battery, some
participants might perform poorly due to anxiety associated
with the uncertainty of whether they qualify for the interven-
tion, independent of their cerebrovascular function. Further-
more, our restrictive study inclusion criteria meant that
relatively healthy women without overt vascular dysfunction
or cognitive impairment were enrolled in the intervention.
Therefore, we cannot draw meaningful interpretations with
the association between 3MS scores and cerebral vasodilator
responsiveness to hypercapnia from our cohort.
Instead, we found that their overall cognitive performance
was directly related to CVR to cognitive test battery that has
greater specificity to detect cognitive deficits in aging women
and sensitivity to detect changes in local blood flow veloc-
ities. In the brain, dynamic regulation of oxygen and glucose
tomatch the metabolic demands of active neurons is achieved
through concerted signaling actions by neurons, glial cells,
and the endothelium. They form a neurovascular coupling
unit to regulate local blood flow through endothelium-
dependent vasodilatation [40]. The compliance of cerebral
vessels is crucial for delivering sufficient blood to regions
of the brain on demand. Thus, the impairment of CVR to
cognitive stimuli may signify the beginning of a chain ofevents leading the progressive decline in brain metabolism,
cognition, and tissue pathology that characterizes dementia
[41]. Perhaps, the deficits in neurovascular coupling are better
predictors of cognitive decline in healthy women. Interest-
ingly, a higher basal mean BFV in the PCA, but not in the
MCA, was linked to better overall cognitive performance
on test battery. Most of the tests in our cognitive test battery
assess the memory domain subserved by the hippocampus.
Given that the hippocampal artery arises from the PCA
[42], this observation warrants further evaluation of CVR to
various cognitive tests in different vessels, notably in the
PCA. In this study, we only explored the global dilatory
responsiveness to hypercapnia in the PCA but not the local
blood flow changes in the PCA during cognitive testing. No
studies have evaluated the association between CVR to
cognitive stimuli in the PCA and the neurovascular coupling
capacity derived from neural activity. Elucidating the mech-
anisms that underpin associations between cognitive function
and efficacy for cerebral perfusion are vital for deriving inter-
ventions to assist postmenopausal women in preserving brain
health. Taken together, the integrity of the neurovascular
coupling unit is more critical for achieving optimal perfor-
mance in healthy, dementia-free older adults.
We found that 3MS scores were unrelated to depressive
symptoms. This was probably due to the lack of range in
the severity of depressive symptoms in our cohort of non-
clinically depressed postmenopausal women or that the sub-
jective ratings for depression failed to account for an
individual’s life situation at time of data collection. Instead
total mood disturbances, which better quantifies the day-
to-day fluctuations of various mood states in nondepressed
individuals, were negatively affecting overall cognitive per-
formance. This is somewhat consistent with existing litera-
ture of an association between depressive symptoms and
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study, as predicted, adult men and women with depression
performed poorly on a verbal fluency test compared with
nondepressed controls. Interestingly, there was no difference
between depressed and nondepressed groups in cerebral
perfusion at rest or during the verbal fluency tests, suggest-
ing a neural activity mismatch may be involved in the path-
ophysiology of mood deficits rather than a simple reduction
in neural activity [44].
We also did not find any relationships between reduced
basal cerebral BFV and severity of depressive symptoms
and total mood disturbances in our sample of postmenopausal
women. In fact, none of our cerebrovascular function param-
eters correlated with depression scores or total mood distur-
bances. Again, the lack of association may be attributable
to the inclusion criteria for this study whereby our partici-
pants are not clinically depressed and without overt vascular
dysfunction. One study has also shown that in cognitively
intact but depressed postmenopausal women, there was no
difference in basal cerebral blood flow between women
with and without depression. However, the authors observed
a blunted rise in cerebral blood flow during the Wisconsin
Card Sorting Task (WCST; CVR to cognitive task), which
correlated with poorer scores on the Mini-Mental State Ex-
amination, one measure of global cognition, but not with
WCST performance [45]. Alleviating depressive symptoms
early inmenopausemay be crucial for reducing the risk of de-
mentia in women later in life. Analysis of the Women’s
Health Initiative Memory Study predicts that depression in
postmenopausal women.65 years old doubles their chances
of developing dementia within 5 years [46]. Although the
integrity of the neurovascular coupling unit is important for
maintaining adequate cerebral blood flow, the underlying
pathophysiology of mood deficits remains unclear. Nonethe-
less, Yao et al showed that the responsiveness of the neurovas-
cular coupling unit could be restored with hormone therapy,
and this was accompanied by improvements in cognitive
function but it did not alleviate depressive symptoms in post-
menopausal women, suggesting that cognitive deficits differ
from mood disorders in their neuropathologic mechanisms,
particularly for women [47].
In conclusion, our exploratory analysis of the relationships
between cerebrovascular function, cognitive performance,
and mood have identified associations between adequate ce-
rebral perfusion both at rest and during cognitive demands
and the resultant cognitive performance in healthy postmeno-
pausal women. Although cognitive performance is negatively
affected by mood disturbances, mood deficits appear unre-
lated to the integrity of cerebrovascular function, at least in
our sample of healthy, nondepressed postmenopausal women.Acknowledgments
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HMRI 14-28).RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using PubMed and Web of Science databases
for articles describing mechanisms that link cerebral
perfusion to cognition and depression in postmeno-
pausal women.
2. Interpretation: While there is an association between
depression and dementia risk and the severity of
cognitive impairment has been attributed to poor ce-
rebral perfusion, there is a lack of evidence to link
poor cerebrovascular function to cognitive deficits
and depressive symptoms in otherwise healthy post-
menopausal women. Impairment of cerebrovascular
function that becomes evident following menopause
is partly due to the loss of beneficial effects of estro-
gen on vascular function.
3. Future directions: Our analysis of baseline data from
a clinical trial in postmenopausal women indicates
direct relationships between intracranial arterial elas-
ticity, integrity of the neurovascular coupling unit
and cognitive performance in healthy postmeno-
pausal women. As such, early interventions to main-
tain optimal function may help attenuate accelerated
cognitive decline.References
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